Benznidazole
Modify Date: 2024-01-03 16:10:36
Benznidazole structure
|
Common Name | Benznidazole | ||
|---|---|---|---|---|
| CAS Number | 22994-85-0 | Molecular Weight | 260.24900 | |
| Density | 1.35g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H12N4O3 | Melting Point | 189-192ºC(lit.) | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of BenznidazoleBenznidazol (Ro 07-1051) is an antiparasitic medication, with an IC50 of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease[1][2]. |
| Name | Benznidazole |
|---|---|
| Synonym | More Synonyms |
| Description | Benznidazol (Ro 07-1051) is an antiparasitic medication, with an IC50 of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Benznidazole (100 mg/kg/day, p.o., 30 days) produces a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart, in mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12 isolate and treated at 180 days post infection (p.i.) (i.e. chronic phase) with Benznidazole[1]. Animal Model: Mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12[1] Dosage: 100 mg/kg/day Administration: Orally for 30 days Result: Produced a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart. |
| References |
| Density | 1.35g/cm3 |
|---|---|
| Melting Point | 189-192ºC(lit.) |
| Molecular Formula | C12H12N4O3 |
| Molecular Weight | 260.24900 |
| Exact Mass | 260.09100 |
| PSA | 92.74000 |
| LogP | 2.02180 |
| Index of Refraction | 1.643 |
| Storage condition | -20℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| RTECS | NI3340000 |
| HS Code | 2933290090 |
| HS Code | 2933290090 |
|---|---|
| Summary | 2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs.
Antimicrob. Agents Chemother. 56(11) , 5821-30, (2012) Nitroheterocyclic prodrugs are used to treat infections caused by Trypanosoma cruzi and Trypanosoma brucei. A key component in selectivity involves a specific activation step mediated by a protein hom... |
|
|
Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole.
Vector Borne Zoonotic Dis. 13(3) , 181-7, (2013) Chagas disease is caused by the protozoan parasite Trypanosoma cruzi, and it affects as many as 10 million people in North and South America, where it represents a major public health problem. T. cruz... |
|
|
Immunosuppression and Chagas disease: a management challenge.
PLoS Negl. Trop. Dis. 7(1) , e1965, (2013) Immunosuppression, which has become an increasingly relevant clinical condition in the last 50 years, modifies the natural history of Trypanosoma cruzi infection in most patients with Chagas disease. ... |
| MFCD00243089 |
| N-benzyl-2-(2-nitroimidazol-1-yl)acetamide |
| 1H-Imidazole-1-acetamide,2-nitro-N-(phenylmethyl)- |